Autosomal recessive conditions are a significant health burden with few treatments. Population carrier screening has been suggested as a means to tackle them. Little is known about the views of affected families despite the potential for direct impacts on them. Data are presented on attitudes among families affected by Spinal Muscular Atrophy (SMA) toward two population screening programs, pre-conception, and prenatal. Data were gathered through qualitative interviews (n ¼ 36) and a survey (n ¼ 337). Eighty-two survey participants had SMA and 255 were family members. The majority were in favor of screening (75%). Reasons for supporting pre-conception screening support were a belief that it would reduce SMA-related terminations and raise awareness of SMA in the population. For prenatal screening, reasons for support included a belief in the importance of informed decision-making and the need to reduce suffering. Key reasons for non-support of pre-conception screening included concerns about carrier stigmatization and social engineering. For prenatal screening, concerns focused on the collateral loss of high quality of life lives affected by SMA. This study highlights that those affected by SMA are predominantly in favor of screening, although pre-conception screening is most favored. While family members and adults with SMA had largely consistent views, perceptions varied according to the severity (type) of SMA, with those affected by SMA type II the least likely to support screening. These findings suggest that screening for SMA is a complex issue for affected families, underscoring the need to consider and include their views when planning and implementing screening programs.
INTRODUCTION
Autosomal recessive conditions, although individually rare, account for approximately 20% of infant mortality worldwide [Bell et al., 2011] . The vast majority of autosomal recessive conditions have severe presentations, relatively high carrier frequencies in the general population and little, if any, effective treatments, fueling the case for their prevention through the use of population screening programs. Indeed, advances in genetic screening technology capability-including next generation sequencing (NGS)-permit screening for whole "panels" of conditions (50þ conditions) simultaneously, and studies are currently underway in the international arena exploring the feasibility of such panel screens for use by the general public [Leo et al., 2016; Plantinga et al., 2016] .
Within the UK NHS healthcare system, genetic testing for autosomal recessive carrier status is usually only offered to people with a family history of that condition. "Cascade" testing (testing of blood relatives of identified carriers/affected individuals) is then usually offered in a step-wise fashion to map the dispersion of the disease-causing trait through a family's bloodline [Morris, 2004] . For the vast majority of people, therefore, the diagnosis of an autosomal recessive disease in their child remains the most common way that they discover their carrier status. This is, furthermore, usually an unforeseen event, as the diagnosis will often be the first in the family's known history.
Through the earlier provision of genetic information (either in the pre-conception or prenatal period), it is argued, genetic screening programs can enhance and expand the reproductive options of these carrier couples while also reducing the number of (unanticipated) births of children with genetic disease [Cornel et al., 2014] . Through the use of pre-conception screening, carrier couples may make use of genetic technologies in their first (rather than subsequent) pregnancies, relieving their reproductive decisions of the constraints associated with already having a child with a serious genetic disease [Human Genetics Commission, 2011] . Preconception screening also extends the reproductive options of carrier couples. Unlike those couples identified through the diagnosis of their child, such couples would have the option to abstain from reproduction altogether, or to reproduce with a different (non-carrier) partner.
A key concern associated with genetic screening programs, however, is that they bestow significant-and potentially burdensome-reproductive decisions on members of the general population who have no previous knowledge, experience, or a priori risk of the condition for which they will be tested [McClaren et al., 2008] . In spite of this, studies have consistently demonstrated favorable attitudes toward expansive genetic screening among the general public [Archibald et al., 2009; Plantinga et al., 2016] , reflecting a widespread social and cultural belief in the significance and benefits of gaining increasing amounts of genomic information [Middleton et al., 1998 [Middleton et al., , 2016 .
Although work has been undertaken to gauge the attitudes of the general public toward genetic screening, far less attention has been paid to the views of families with experience of the conditions for which screening could be offered, with a few notable exceptions [Skinner et al., 2003; Maxwell et al., 2011; Pisnoli et al., 2016] . However, affected families represent an important stakeholder group; such families possess expert "experiential knowledge" [Abel and Browner, 1998; Boardman, 2010 Boardman, , 2014 of the condition in question and unparalleled insight into the realities of its day-today impact. This expert knowledge is of direct relevance to policy decision-making around which conditions should, and should not be, included in genetic screening programs.
Aside from policy implications, the paucity of research on the views of affected families toward population screening is concerning because such families are set to be directly-and potentially significantly-impacted by their introduction [Kellog et al., 2016] . Such impacts might include changes in public attitudes toward the condition [Stotko, 2009] , reductions in research funding for treatments and social isolation as a consequence of a reduced birth-rate of people with the same condition. This paper addresses this identified gap in evidence and understanding by exploring the views of affected families and individuals toward population level pre-conception and prenatal genetic screening using one particular autosomal recessive disorder, Spinal Muscular Atrophy (SMA), as an example.
BACKGROUND
SMA has been identified as the most common genetic cause of infant death worldwide [Munsat and Davies, 1992] . It is usually caused by either a point mutation (a single nucleotide is altered) or a deletion mutation (a section of DNA is missing) of the SMN1 gene, located on chromosome 5 Clermont et al., 1995] . It is characterized by loss of the alpha motor neurones of the spinal cord (neurones required to transmit nerve impulses from the brain to muscle), resulting in symmetrical and progressive atrophy of the voluntary muscles of the limbs and trunk, as well as weakening of the inter-costal muscles (muscles used to support breathing). It is sub-classified into distinct "types" (0-IV), based on the age of onset and severity (measured by achievement of gross motor milestones, primarily sitting and walking) [Lunn and Wang, 2008] (Table I) . From these types, the disease trajectory can be estimated, including anticipated life expectancy, which varies drastically across the types of SMA. Babies diagnosed with type 0 or I SMA typically have a significantly shortened lifespan, with death occurring either before, or shortly after, birth (in the case of type 0) or by 18 months (type I). Children diagnosed with type II are usually never able to walk or sit independently, but their impairment typically remains relatively static over the life course, and lifespan is usually near-normal. Types III and IV onset later, and ambulation is often achieved before onset of the disease, which is in late childhood (type III) or adulthood (type IV). These milder forms of SMA involve gradual deterioration in abilities over time, but lifespan is usually unaffected.
Although the typing system for SMA has long been used as a shorthand for disease severity both within and without the medical profession, it is also acknowledged that this way of categorizing SMA results in types with a high degree of overlap and broad ranges of disease severity within them [Dubowitz, 1991] . Pilot studies using SMN2-copy number to type SMA at diagnosis have been reported. These include a pre-conception screening program in the United States [Prior et al., 2010] and a prenatal screening program in Taiwan [Su et al., 2011] . These pilot studies suggest that while most patients can be stratified by SMN2 copy number, the overlap means patients whose symptoms lie on the boundaries between types can be mis-typed. Indeed, attempts to refine the classifications through linking genetic findings, primarily SMN2 copy number, to disease severity have thus far been unable to adequately explain the co-occurrence of different types of SMA within one family, and it is now more widely accepted that there are a number of confounding factors that influence disease severity, for example, Plastin 3 [Opera et al., 2008] . Therefore, while typing is able to differentiate between the extremes of the clinical spectrum, additional work is needed to produce a stratification system that accurately classifies at the type I/type II and type II/type III interface.
Internationally, approaches to SMA screening vary significantly, with some countries implementing compulsory premarital carrier screening for SMA (Qatar), with others offering screening through state-subsidized health care plans (Israel, Australia). Within the UK, SMA screening may be purchased privately through direct-to-consumer genetic testing companies, but when set against UK National Screening Committee criteria (the advisory body to government on issues related to screening) the potential for mis-typing was judged to be a major obstacle to screening implementation in the last policy review [Cartwright, 2012] .
As well as technological concerns, there is also limited evidence within the literature on attitudes toward SMA screening among both the general public (with a few notable exceptions [Prior et al., 2010; Rothwell et al., 2013; Norton et al., 2014] ) and families living with SMA. Where families living with SMA have been included in screening studies, numbers have typically been low, only 5 parents of a child with SMA were included in Wood et al.'s [2014] US-based study of newborn screening and 28 in Lawton et al.'s [2015] Australian study. Furthermore, neither of these studies included individuals with SMA themselves. No previous study, therefore, has explored the views of families and adults currently living with SMA towards population level genetic screening for the condition. This research fills this gap in the literature by presenting the views of people currently living with SMA (either through having it themselves or having an affected family member) in the UK on two different types of screening program: (i) a pre-conception genetic screening program (whereby would-be parents are screened prior to conception to identify whether they are SMA carriers) and (ii) a prenatal genetic screening program (whereby the parents are screened for their SMA carrier status after a pregnancy is established, including genetic testing of the fetus where indicated). While data were also collected within this study on attitudes toward newborn screening, as newborn screening for SMA raises unique issues distinct to those associated with carrier screening [Swoboda, 2010] , these data will be presented separately.
MATERIALS AND METHODS
An exploratory sequential mixed methods research design was adopted to address the complex and multi-faceted question of screening for SMA. The research took place in three distinct phases which are outlined below.
Qualitative Interviews: Phase I
In-depth qualitative interviews were conducted with 36 people who either have SMA themselves, or have SMA in their family, recruited through the main support group for families living with SMA, SMA Support UK (see Table II for a breakdown of interview participants). A sub-set (n ¼ 17) of these interviews were conducted as follow-up interviews to a previous study around uses of prenatal testing and selective termination in families affected by SMA [Boardman, 2010] . Advertisements were placed in SMA Support UK's quarterly newsletter and electronic newsletters to call for participants. Interviews were designed to explore experiences with SMA, views around, and experiences of, genetic testing technologies and selective termination, as well as perceptions of population screening for SMA. Respondents were eligible for interview if they were aged 18 or over, English speaking and either had SMA themselves, or had at least one diagnosis of SMA in their family.
The various calls for participants led to responses from 41 individuals (five individuals were excluded; four because the diagnosis in their family was of Muscular Dystrophy; and one because they were under 18). Out of the 36 audio-recorded interviews that were carried out, 31 were completed over the telephone and five face-to-face. The interview recordings were transcribed verbatim (with names and identifiers removed or changed) and the data analyzed using qualitative data analysis software, Nvivo10. A constructivist approach to grounded theory data analysis was used.
Initially, "open coding" of the data was carried out which was largely descriptive, before hierarchical coding. A process of coding, refinement of concepts (through data interpretation), followed by re-coding was carried out over a period of five months until "theoretical saturation" had occurred [Glaser and Strauss, 1967] .
The qualitative data revealed a complex picture of attitudes toward screening, and seven key overarching themes emerged, as set out in Table III . These overarching themes were not identified by the number of times they appeared in participants' responses (indeed, some themes appeared far more frequently than others), but rather they comprise an exhaustive list of all the overarching themes under which all participants' accounts could be coded. These seven themes were subsequently used to delineate the key domains of the SMA Screening Survey (UK). Having identified the broad domains of the survey directly from the qualitative themes, the domains were next transformed into single sentence "attitude/belief" statements, which were in turn developed into quantitative survey questions through the use of a Lickert scale. Where possible, verbatim text from participants' interviews was used to create these attitude statements. Through this process, the qualitative analysis directly informed the content of the survey. Questions designed to capture demographic information from respondents (such as educational attainment, religious faith, and ethnicity) were either directly replicated from, or appear as modified versions of, questions from the 2011 UK Census survey.
As well as the underpinning qualitative work, the survey was also passed through three expert panels. The first of these panels comprised six staff members from SMA Support UK. The second group consisted of four members of SMA Patient Registry staff. These two professional panels reviewed the survey once it had been completed in first draft form and offered feedback on the questions as well as advice on the implementation strategy. A separate expert review panel was also established that was made up of people living with SMA. Nine individuals sat on this panel, three of whom had SMA themselves and six of whom had a relative with SMA. This panel met to discuss the qualitative analysis and early design of the survey. Once the SMA Screening Survey (UK) had been drafted, they were contacted once again to undertake a cognitive interview. "Cognitive interviewing" is a widely used technique that uses indepth interviewing techniques in order to explore the mental processes that participants use to answer survey questions [Willis, 2005] . Six members of the expert review panel undertook such an interview. Ethical approval for the SMA Screening Survey (UK) was granted by the Biomedical and Scientific Research Ethics Committee in July 2014.
Quantitative data collection was carried out over a period of 10 months, from September 1, 2014 to June 30, 2015. Two versions of the survey were made available, an online version (hosted on a secure website) and a paper copy. The survey was distributed to families living with SMA through a variety of channels. Firstly, all members of SMA Support UK (1,500 households) received a paper copy of the survey (and a pre-paid returns envelope) in September 2014 together with their quarterly newsletter which included an article on the project. Participants were encouraged to distribute the survey to interested family members/friends affected by SMA. A reminder to complete and return the survey was sent out in December 2014. Postal returns were all processed using data scanning technology to reduce human error.
A link to the online survey was additionally included on SMA Support UK's webpage with a link to it distributed through their social networking pages (Facebook and Twitter). The link was also emailed to all members of the SMA Patient Registry, which holds the details of 538 people diagnosed with SMA and their families, as part of their quarterly newsletter. A reminder was sent out to Patient Registry members in April 2015.
Finally, the survey was advertised through the research project's webpage and through its associated social networking accounts (Facebook and Twitter), and a link was placed on two private Facebook group pages dedicated to supporting people with SMA. This was done in order to reach people with SMA who might not be affiliates of the support group or Patient Registry.
People were invited to complete the survey if they were over 18 and either had SMA themselves, or at least one diagnosis of SMA in The questions were split into seven core themes (medicalization of reproduction; eugenics/social engineering; public visability of SMA and social support; stigma; value of people with SMA; prevention of suffering/genetic responsibility and informed decision-making). Each theme contained specific attitude statements.
the family. People affected by one the variant forms of SMA (Spinal Muscular Atrophy and Respiratory Distress, Spinal Bulbar Muscular Atrophy) were also invited to take part (see Table I for descriptions). No restrictions were placed on the nature of the familial relationship: step, adopted, and fostered family members were included. The definition of "family member" was kept broad and included non-biological relatives as the social relationship to the person with SMA was considered as important than the biological relatedness of the person in dictating reproductive attitudes [Boardman, 2010 [Boardman, , 2014 . Furthermore, it was considered important for the analysis to include people with varying degrees of proximity to SMA.
TABLE III. Characteristics and Demographics of Survey Responders
Demographics are shown for all responders (n ¼ 337), responders associated with SMA families (families; n ¼ 225), and individuals with SMA (patients; n ¼ 82). Response distributions were compared between families and patients and significant differences were assessed using chi-squared analysis (P-value). Significant differences are highlighted (P < 0.05).
Survey Data Stratification and Statistical Analysis
Responses to each question were stratified as follows: gender (male 1 vs. female 0); age ( [0] ). For all questions regarding screening answers were stratified as either agree/strongly agree (1) or other (0). This was done because it allowed the simplest way of assessing the positive views of respondents.
The attitudes of families and adults with SMA toward preconception genetic screening (PCGS) and prenatal screening were compared to determine if there were any statistical differences. The following sub-group analyses were performed: all responders were analyzed collectively to identify any overriding trends (all responders). Responses from families (all) and adults with SMA (all) were compared to determine if living the disease altered views (NB this analysis included all responders, including the adult living with type IV SMA and the rarer severe forms [SMARD] ). Sub-analyses on responders associated with the three most prevalent childhood forms of SMA (type I, II, and III) were then performed. Responses from families associated with type I were compared with responses from families with milder forms (type II/III SMA [combined] , type II alone, and type III alone)-to determine if severity altered families views. Responses were compared between families and adults with SMA, to determine if the relationship to SMA affects views (when severity is standardized). This analysis was split into three: (i) type II-associated responders; (ii) type III-associated responders; and (iii) type II/III combined (the combined analysis was performed to facilitate logistic regression analysis based on the relatively low number of adults with SMA in the two sub-groups. Finally, responses from adults with type II were compared to adults with type III, and responses form type II families were compared to type III families. This assessed whether the severity and age of diagnosis impacts views, and whether any differences were seen in both families and adults living with the disease. For the subgroup analysis, families members associated with more than one form of the disease were classified according the most severe form within their family (e.g., a family associated with type I and II would be classified as a type I family).
In each of the sub-group analyses, the individual questions were assessed and then responses correlated against support for screening. For each question the number of "agree" versus "other" responses were reported and statistical differences between the subgroups were assessed using a chi-squared analysis (Graphpad Prism software, v6). Associations between positive "agree" responses to each question were assessed using binary logistic regression (performed against Q19g (I would support a preconception genetic screen for SMA), Q20i (I would support a prenatal screening program for SMA). Logistic regression was performed using SPSS v22 (IBM).
Re-Interrogation of Qualitative Data: Phase III
After statistical analysis of the survey was completed, the qualitative data was returned to. Data that were coded for the key themes and ideas that emerged as significant from the quantitative analysis were explored further within the qualitative data. This technique of returning to the qualitative data in an exploratory sequential mixed methods research design is particularly useful in drawing out the nuances, complexities and contradictions in participants' views that might otherwise be missed by use of statistical analysis alone, while retaining the generalizability of findings achieved through quantitative methods. For a topic area as complex as screening, this technique proved particularly useful in illuminating and clarifying the key findings of the study. Excerpts from the qualitative data were selected for inclusion in this paper if they particularly eloquently reflected or clarified a key finding.
RESULTS

Cohort Descriptive Characteristics
In total, there were 146 online completions of the survey, and 191 postal returns. Of the 337 participants, 255 were family members of people with SMA (75.7%), and 82 had SMA themselves (24.3%; Table III ). Basic descriptive analysis highlighted most participants were female (74.4%); aged between 35 and 55 years (52%); were not educated to degree level (63.8%); were religious (55%); parents (82%); had lived/were living with someone with SMA (82%); and had experience with SMA types 0, I or II (69.4%) ( Table III) . The remainder of the sample (31.6%) were affected by rarer forms of SMA (type IV, Spinal Bulbar Muscular Atrophy, Spinal Muscular Atrophy and Respiratory Distress.) A small sub-set of participants were either pregnant or trying to get pregnant (7.4%) (Table III) .
Pre-Conception Genetic Screening (PCGS)
Overall, 77.2% of survey participants were in favor of PCGS, with no statistical differences between families and adults with SMA (SMA families 79.6% vs. adults with SMA 69.5%; P ¼ 0.16) or families and adults associated with type II/III SMA (type II/III families 72% vs. type II/III adults with SMA 76%, P ¼ 0.71; Table IV ). However, there was statistically more support for PCGS in type I SMA families (88%) compared with type II/III SMA families (72%; P ¼ 0.002) and type II families alone (72%; P ¼ 0.005) ( Table IV) . The lowest level of support was reported among adults with type II SMA (63%), which was significantly lower than support among adults with type III SMA (94%; P ¼ 0.008; Table IV) .
Interestingly, while the majority of participants agreed that PCGS was important because it would reduce the number of SMA-associated terminations and would raise awareness of SMA in the general population, there were significant differences in the type II associated participants when compared with other sub-groups (Table IV) . For example, fewer type II adults thought PCGS would reduce the number of terminations, when compared to type III adults with SMA (56% vs. 80%, respectively; P ¼ 0.05; Table IV ). There was also a significant difference between type I and type II families when assessing if a carrier screen would raise general awareness of the disease (96% vs. 80%, respectively; P ¼ 0.0005; Table IV) . Interestingly, no similar disagreements were observed between type I and type III families, suggesting that participants associated with type II have distinct views on screening and the disease, while participants associated with the severe (type 0/I) and mild (types III/IV) ends of the spectrum appear to be in closer agreement.
Comparing families and adults with SMA highlighted that a higher proportion of adults thought carrier screening would result in carrier stigmatisation (42%) compared to family members (17%; P < 0.0001; Table IV); this difference was seen in all patient versus family sub-group analyses performed. In addition, within the families, it was clear that the type II and III family members saw the issue of stigmatization as a larger problem than the type I families (Table IV) . However, this difference could be explained by the potential long-term exposure to stigmatization experienced by type II/III families when compared to type I families, whose experience with SMA is comparatively shorter.
A higher proportion of adults with SMA also thought PCGS was a form of social engineering (44%) compared with families (20%; P < 0.0001; Table IV ). This difference was predominantly driven by adults with type II SMA, 56% of whom agreed that PCGS is a form of social engineering (Table IV) . However, it should be noted that in each of the other sub-groups, the majority of participants did not agree that screening will stigmatize or that it is a form of social engineering.
PCGS Drivers: Why Do Participants Want PCGS?
Univariate logistic regression analysis confirmed the direct comparison analysis, with all participants and sub-groups in favor of PCGS believing it will reduce the number of SMA-related terminations and increase the awareness of SMA in the general population (Table VI) . Participants in favor of PCGS, in general, did not agree it will result in stigmatization or that it is a form of social engineering (Table V) . This is also the case for type II/III associated participants, again highlighting that although there is an increased proportion of these participants who did not overtly support PCGS, the majority do.
Prenatal Genetic Screening
The attitudes of family members and adults with SMA toward prenatal genetic screening (PGS) were compared to determine if there were any statistical differences using the same four sub-group analyses used for PCGS (Table VI) . Overall, 76.3% of participants were in favor of PGS, with no statistical difference between families and adults with SMA (SMA families 78.4% vs. SMA adults with SMA 69.5%; P ¼ 0.25; Table VI), or families and adults associated with type II/III SMA (type II/III families 71% vs. type II/III adults with SMA 67%, P ¼ 0.72; Table VI). However, as with PCGS, there was a significant differences within family and patient sub-groups: (i) type I families showed a greater level of support (88%) compared to type II (72%) and type III (68%) families and (ii) type II adults with SMA showed lower levels of support (52%) compared to type III adults with SMA (81%), again highlighting the divergent views of the intermediate adults with SMA (Table VI) .
TABLE IV. Response Summaries for Questions Assessing Views on Pre-Conception Genetic Screening (PCGS)
Response breakdowns are shown for family sub-groups (all, Type I, Type II/III combined, Type II, and Type III) and patient sub-groups (all, Type II/III combined, Type II, and Type III). Responses for each question were stratified as "agree" versus "other" (other ¼ disagree and neither disagree nor agree). This stratification was used to enable binominal logistic regression of each sub-group (Table V) . Response distributions were compared using chi-squared analysis (P-value; significant differences are highlighted (P < 0.05).
Across the sub-groups, there was agreement that PGS will allow families to make informed decisions and will raise awareness of SMA in the general population. There was a noticeable difference in the sub-group analysis on whether PGS will prevent unnecessary suffering: (i) fewer adults with SMA (43%) agreed with this statement compared with family members (65%; P ¼ 0.001; Table VI) , with type II adults displaying the lowest amount of agreement (22%) and (ii) fewer type II and type III families (52% and 59%, respectively) agreed with this statement compared to type I families (79%; Table VI ). The SMA Screening Survey (UK) contained two core "negative" statements: (i) identifying SMA in pregnancy will inevitably lead to less people with SMA coming into the world who could have lived fulfilling lives and (ii) it would be a loss to society to have less people with SMA coming into the world. Comparing responses for the first of these questions, there was no statistical difference between families (51%) and adults with SMA (62%; P ¼ 0.18) when analyzed collectively (Table VI) . However, there was a difference between type II families (66%) and type I (41%; P ¼ 0.0007; 
Prenatal Genetic Screening: Ability to Type
A lack of clinical evidence that SMA can be typed at diagnosis was identified as a substantial obstacle to SMA screening when set against UK National Screening Committee criteria [Cartwright, 2012] . Therefore, a central question for PGS is whether families and adults with SMA want screening, even if the screen cannot determine the type of SMA. When analyzed collectively, there was no significant difference between families (69%) and adults with SMA (63%) who think screening is useful even if type cannot be determined (P ¼ 0.64; Table VI). However, there was a significant difference between the type II families (60%) and type I SMA families (77%; P ¼ 0.01; Table VI); this lower level of support for screening without typing was also seen in type II adults with SMA (44%; Table VI); suggests that typing is more of an issue for the families and adults associated with type II SMA (Table VI) .
TABLE V. Logistic Regression Analysis Highlighting Positive and Negative Drivers Associated With Responders Views on Preconception Genetic Screening (PCGS)
Odds ratios are presented for response breakdowns are shown for family sub-groups (all, Type I, Type II/III combined, Type II, and Type III) and patient sub-groups (all, Type II/III combined, Type II, and Type III). Responses for each question were stratified as "agree" versus "other" (other ¼ disagree and neither disagree nor agree). Odds ratios (OR) show the likelihood that responders who agreed with each individual question (variable) were also in favor of preconception genetic screening (PCGS). Positive drivers are indicated by a odds ratio >1 and a P-value <0.05); negative drivers are indicated by an odds ration <1 and a P-value <0.05). Significant drivers are highlighted in gray. Several ORs are presented as NR (not returned); this is because of the low number of responders and included "other" responses.
Prenatal Genetic Screening Drivers: Why Do Participants Want Prenatal Screening?
Univariate logistic regression analysis confirmed the direct comparison analysis, with participants and sub-groups in favor of PGS in generally believing that it will allow informed decisions, will prevent unnecessary suffering and raise awareness of SMA in the general population (Table VIII) . In addition, all participants in favor of also generally agreed that screening was important, even if the type could not be determined (Table VII) . Participants in favor of PGS, with the exception of type II/III participants, generally did not agree it will result in fewer adults with SMA being born who could live fulfilling lives, or that this would be a loss to society (Table VII) . It is interesting to note that this highlighted a statistical difference between type II/III families and adults with type II/III SMA (Table VII) and confirms the difference in how the two groups view the impact on society (Table VI) .
Views on SMA: Families Versus Adults With SMA
Our data suggests interesting differences between adults with SMA and families, as well as between families associated with different SMA types. To analyze this further, we analyzed responses to questions designed to tests general views of SMA (Table VIII) . All participants, irrespective of their sub-group, agreed that quality of life varies between SMA types (Table VIII) . However, this was the only question with standardized agreement.
Compared with adults with SMA, more family members thought (i) SMA causes people to suffer (families 80% vs. adults with SMA 53%, P < 0.0001); (ii) people with SMA have heightened intelligence (families 61% vs. adults with SMA 40%, P < 0.0001); and (iii) SMA families and adults are well supported by society (families 29% vs. adults with SMA 15%, P ¼ 0.02) (Table VIII) . Sub-analysis shows the difference in views on whether SMA causes people to suffer between families and adults with SMA was maintained when type II/III families (74%) and type II/III adults with SMA (47%) were compared (P < 0.0001; Table VIII) . Interestingly, the analysis confirmed that type III adults with SMA had a more negative view of the disease than type II adults with SMA: (i) comparatively more adults with type III SMA thought SMA causes people to suffer (65% vs. 26%; P ¼ 0.004; Table VIII) and (ii) comparatively fewer adults with type III SMA thought people with SMA have heightened intelligence (35% vs. 74%; 0.004; Table VIII ).
Qualitative Data
That screening is a complex issue for families that can elucidate variant views among affected families was not only reflected in the quantitative data, but also in the 36 qualitative interviews. Upon completion of the quantitative analysis, the qualitative data were returned to in order to better understand the key statistical findings.
Many participants confirmed that the nature of their experience with SMA was critical to determining their attitudes. One participant, Sarah, a parent of an adolescent child with type III SMA commented on this diversity in the following way:
TABLE VI. Response Summaries for Questions Assessing Views on Prenatal Genetic Screening
Response breakdowns are shown for family sub-groups (all, Type I, Type II/III combined, Type II, and Type III) and patient sub-groups (all, Type II/III combined, Type II, and Type III). Responses for each question were stratified as "agree" versus "other" (other ¼ disagree and neither disagree nor agree). This stratification was used to enable binominal logistic regression of each sub-group (Table VII) . Response distributions were compared using chi-squared analysis (P-value; significant differences are highlighted (P < 0.05).
You're always going to get mixed views if you ask families about screening, because it cuts close to the bone really, doesn't it? You won't just hear what people think about screening, what you're also hearing about is how people cope with their SMA, what they've experienced and of course their views on abortion which is a moral quagmire at the best of times! I think this is particularly true for a condition like SMA, you're always going to get differences of opinion because the condition is so different. We've all got the same condition, but we're fighting our own personal battles a lot of the time.
As Sarah eloquently expressed, views towards screening were inextricably bound up with participants' personal experiences of the condition itself. 'Personal battles' came to be translated into reproductive attitudes; they formed the basis of how the condition was conceptualized, and consequently views towards screening for it. A key way in which this divergence emerged in the conceptualization of SMA was within the responses of adults living with type II SMA. This group emerged from the quantitative analysis as the group least likely to support any form of screening at all, and most likely to actively raise objections to screening, on the grounds of their relatively positive view of the condition. For many adults living with SMA, such as Charlotte, who feel comfortable with their condition and are living full and satisfying lives with access to independent living work and parenthood, "eradicating" SMA through a screening program was simply not a priority when set alongside other goals, such as improving support and care for those currently living with SMA. However, this view contrasted with adults affected by type III SMA, many of whom had different experiences with the condition. Rory is in his early 40s and has type III SMA. He described his views in the following way:
I support screening really. At the end of the day, SMA is a disease and it robs people of life and life experiences that they could have had, so if that's preventable for someone, shouldn't that be the case? In my case, I was able to walk at one point-I know how that feels-and now I can't and that's just had massive repercussions in my life, massive, and also in the lives of those around me. I have to rely on others now, whereas I didn't before, and that's massively hard to accept. . . [. . .] . . .It's a bit like a bereavement in some ways, you know? You mourn your old life and everything in it. So yeah, it's just common sense to me that you would want to stop that happening. I can't understand anyone who would think otherwise. While Rory's SMA would be medically defined as less severe than Charlotte's (who had been unable to walk since birth), the contrast between their two perspectives on the condition were stark, and this contrast was also underpinned by the quantitative evidence.
DISCUSSION
This research is the first to systematically report the views of families living with SMA towards population level genetic screening in the UK. Our sample includes a range of severities and sub-types of SMA, as well as affected adults, who have previously been omitted from previous studies of attitudes toward screening [Wood et al., 2014; Lawton et al., 2015] . This study has demonstrated that the majority of participants (75%) with experience of SMA are in favor of some form of screening program for the condition, irrespective of the form (pre-conception/prenatal) and irrespective of the potential for mis-typing, even though this was a major stumbling block to the implementation of a screening program in the UK in the 2013 review [Cartwright, 2012] . Pre-conception genetic screening fostered slightly more support (77%) than prenatal screening (76%), which echoes the findings of Lawton's Australian study [2015] . Moreover, attitudes to screening were highly correlated with perceptions of quality of life, with those perceiving the lowest SMA-related quality of life most likely to support the introduction of population level genetic screening for the condition than those who perceived high quality of life.
However, while the majority of participants supported SMA screening, a significant minority (25%) did not support either screening program. This level of non-support appears high when compared to the findings of similar studies such as that by Maxwell et al. [2011] where high support for both prenatal and preconception genetic screening among family members and adults living with Cystic Fibrosis was discovered.
Ambivalence towards SMA screening in this SMA-associated population may in part stem from the wide spectrum of severities associated with the condition, the different ways in which participants came to know SMA (either through a family member, or having it themselves) and the diversity of experiences emerging from these standpoints. Indeed, there were marked differences between the views of adults with SMA and family members. These differences emerged in the way quality of life with the condition was perceived and rated (adults with SMA consistently rated their quality of life with SMA above that of family members), but also in terms of screening support, with more family members supporting screening than affected adults. Differences in quality of life perceptions between disabled people and their family members have been widely reported elsewhere in the literature, with disabled people consistently rating their quality of life as higher than their family members' evaluations of it [Young and McNicoll, 1998; Albrecht and Devlieger, 1999] . However, sub-analysis of type II/III families versus adults with SMA highlighted that the majority of these differences were determined by the severity of the disease they are associated with rather than whether or not they were diagnosed with SMA themselves. While type I associated families demonstrated wide-reaching support for screening-presumably because their experience with SMA is negative in the extreme-participants associated with milder forms of the disease have comparatively lower levels of support.
It is noteworthy that adults living with type II SMA were the group least likely to support any form of screening and the most likely to actively oppose it. While it is perhaps unsurprising that adults with SMA who are living happy and fulfilled lives would be less likely to support screening than family members living with types 0/I SMA (who usually had experienced the death of their child at a very young age), this finding remained true even when compared to adults diagnosed with the (clinically) milder form of the disease, type III. As highlighted by both the quantitative and qualitative data (Rory), those affected by type III SMA perceived more suffering around the experience of SMA, and as such were more likely to want screening for it. Shakespeare [2006] has noted that the perspectives of people who lives are affected by a static impairment (such as those with type II SMA) are often very different to those whose impairments are degenerative (types III and IV SMA) or associated with pain and/or premature death (types 0/I SMA). While people affected by relatively static impairments from birth are often "well adjusted" to their condition, identify with it and organize their lives around it, people who experience periods of rapid and/or severe decline must go through continual cycles of crisis and then re-adjustment to an everchanging reality [Shakespeare, 2006: 106-107] . As exemplified by Rory's account, many participants with late childhood or adult-onset types of SMA (type III, SBMA) reported a sense of loss and grief as their muscle strength deteriorated over time. Similarly, for parents whose child is diagnosed with type I SMA, this experience can be described as akin to a continual process of "biographical disruption" [Bury, 1982] followed by "biographical repair," whereby the parents transition from being a parent of a "healthy" child to parents of a child "in crisis' [Young et al., 2002] . Conversely, for adults living with type II SMA like Charlotte, the social, cultural, and physical landscape of their everyday lives was often demarcated as the most significant mediator of the quality of their lives, rendering screening largely irrelevant. These contrasting experiential realities of life with the condition fed into the ways that quality of life with SMA was perceived, and ultimately how far screening was supported. This study, by focusing on the views of affected families, has highlighted that while the majority of respondents generally want some form of screening for SMA (irrespective of the ability to determine type of SMA), experiences with the condition were most critical in determining attitudes. Indeed, it was the nature of that experience (i.e., whether of bereavement, deteriorating symptoms or of a fixed impairment), more so than a person's relationship to that experience (i.e., whether they have the condition, or someone else in their family does) that modified attitudes.
This study underscores the need to include both affected adults and affected family members in debates around screening for SMA, as well as in debates around screening for similarly variable genetic disorders. Understanding the value and significance of prior experiences with the disease in formulating reproductive attitudes and decisions is highly relevant to anticipating the social and ethical ramifications of such genetic screening and highlights the need to interrogate patients' previous experiences with disability in the context of any population level genetic screening program.
Further research is indicated to explore how such attitudes might vary across families living with different types of genetic condition, particularly those with contrasting features to SMA (e.g., cognitive/behavioral symptoms, conditions associated with pain, and treatable conditions), to further explore how experience with different types of condition impacts on reproductive screening attitudes.
LIMITATIONS
Due to confidentiality and data protection issues, no identifiable data were asked of individuals who participated in the SMA Screening Survey (UK), including IP addresses (where the survey was completed online). This meant that there was no mechanism by which to prevent an individual completing multiple surveys. Moreover, there was no way of verifying that the participant fitted the inclusion criteria to participate in the survey. Participants were furthermore accessed through a national support group, personal networks, and a patient registry rather than neuromuscular clinics, which may have introduced bias. Due to the very poor prognoses associated with types 0 and I SMA, the adults with SMA who participated in the survey were largely affected with clinically milder forms of the disease (although two participating adults reported that they had a diagnosis of type I SMA, and all types of SMA can be associated with significant disability and disease burden), which may have impacted on how the disease was presented and the differences in perceptions of quality of life associated with SMA between adults living with it and parents of babies who died of types 0 or I SMA. Response breakdowns are shown for family sub-groups (all, Type I, Type II/III combined, Type II, and Type III) and patient sub-groups (all, Type II/III combined, Type II, and Type III). Responses for each question were stratified as "agree" versus "other" (other ¼ disagree and neither disagree nor agree). Response distributions were compared using chi-squared analysis (P-value; significant differences are highlighted (P < 0.05).
ACKNOWLEDGMENTS
to acknowledge with gratitude the guidance and support with recruitment provided by SMA Support UK (formerly the Jennifer Trust for SMA) and the UK SMA Patient Registry. Special thanks go to the families and adults living with SMA who both advised on, and participated in this study.
